REFERENCES
- Hospice and Palliative Nurses Association. Core Curriculum for the Generalist Hospice and Palliative Nurse. 3rd ed. Dubuque, IA: Kendall Hunt; 2010.
- Jalmsell L, Kreicbergs U, Onelov E, et al. Symptoms affecting children with malignancies during the last month of life: a nationwide follow-up. Pediatrics. 2006;117:1314–1320.
- Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2000;18:S3–S13.
- Ferrante FM. Principles of opioid pharmacotherapy: practical implications of basic mechanisms. J Pain Symptom Manage 1996;11:265–273.
- DuPen A, Shen D, Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manage Nurs. 2007;8:113–121.
- Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008;4:123–130.
- Bower DK. Opioid-induced neurotoxicity: too much of a good thing. J Palliat Med. 2008;11:947–948.
- Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313.
- Kozlov M, Anderson MA, Sparbel KJH. Opioid-induced neurotoxicity in the hospice patient. J Hosp Palliat Nurs. 2011;13:341–346.
- Prommer E. Rotating methadone to other opioids: a lesson in the mechanisms of opioid tolerance and opioid-induced pain. J Palliat Med. 2006;9:488–493.
- Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12: 679–684.
- Okon TR, George ML. Fentanyl-induced neurotoxicity and paradoxic pain. J Pain Symptom Manage. 2008;35:327–333.
- Adair JC, el-Nachef A, Cutler P. Fentanyl neurotoxicity. Ann Emerg Med 1996;27:791e792.
- Fishman, S., Ballantyne, J., Rathmell, J. P., & Bonica, J. J. (2010). Bonica's management of pain. 4th Edition. Baltimore, MD: Lippincott, Williams & Wilkins.
- Magnusson J, Mulder J. Opioid induced neurotoxicity. Communication. 2001:6–8.
- Razaq M, Balicas MNP, Mankan N. Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment. Am J Ther. 2007;14:414–416.
- Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008;9:724–727.
- Ackerman WE 3rd. Paroxysmal opioid-induced pain and hyperalgesia. J Ky Med Assoc. 2006;104:419–423.
- Ferrell BR, Coyle N, Paice J (Eds.). Oxford Textbook of Palliative Nursing. 3rd ed. Oxford, UK: Oxford University Press; 2010:1246.
- Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. 2007;21:15–26.
- Vanderah TW, Suenaga NMH, Ossipov MH Jr, Malan TP, Lai J. Tonic Descending Facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. 2001;21:279–286.
- Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29:661–666. Retrieved April 17, 2013 from: http://www.ncbi.nlm.nih.gov/pubmed/23540512.
- Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther. 2009;31:2804–2818.
- Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28:401–417.